Cunningham, Kaitlynne N. http://orcid.org/0000-0001-7826-1890
Rosmarin, David http://orcid.org/0000-0003-2786-0708
Article History
Accepted: 19 December 2022
First Online: 30 January 2023
Declarations
:
: Kaitlynne N. Cunningham declares no conflicts of interest. David Rosmarin has received honoraria as a consultant for AbbVie, Abcuro, AltruBio, Arena, Boehringer-Ingelheim, Bristol Myers Squibb, Celgene, Concert, CSL Behring, Dermavant, Dermira, Incyte, Janssen, Kyowa Kirin, Lilly, Novartis, Pfizer, Regeneron, Revolo Biotherapeutics, Sanofi, Sun Pharmaceuticals, UCB, and VielaBio; has received research support from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Dermira, Galderma, Incyte, Janssen, Lilly, Merck, Novartis, Pfizer, and Regeneron Pharmaceuticals Inc; and has served as a paid speaker for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Incyte, Janssen, Lilly, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., and Sanofi.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Kaitlynne N. Cunningham wrote the manuscript, completed the literature review, edited the manuscript, and read and approved the final version of the manuscript for publication. David Rosmarin supervised the work, critically reviewed and edited the manuscript, and read and approved the final version of the manuscript for publication.